TransMedics Lifts FY26 Revenue Floor to $737M, Excluding PAD Aviation
TMDX sits 47% above its 52-week low of $60.105.
Summary
TransMedics raised the low end of its FY26 revenue guidance to $737M-$757M, excluding its PAD Aviation segment. The move signals confidence in core organ transplant logistics, lifting the floor from a prior undisclosed level. This follows a May proxy filing seeking 2.75M additional shares for its incentive plan, hinting at ongoing equity compensation needs. The update provides a cleaner view of the base business, stripping out the aviation unit. With a $2.8B market cap, the raised floor is a material positive signal for the year's trajectory.
At the time of this announcement, TMDX was trading at $88.50 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.8B. The 52-week trading range was $60.11 to $156.00. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Dow Jones Newswires.